Literature DB >> 6639840

Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension.

P C Rubin, L Butters, R A Low, J L Reid.   

Abstract

The disposition and effect of orally administered prazosin have been studied in eight women with hypertension which was uncontrolled by beta-adrenoceptor blockade during the last trimester of pregnancy. Results were compared with healthy men of similar age. The median time to peak concentration was 165 min during pregnancy and 120 min in the men (P less than 0.04). Area under the concentration vs time curve was 3914 ng l-1 min in pregnancy and 2439 ng l-1 min in the men (P less than 0.06). Mean elimination half-life was 171 min in the pregnant women and 130 min in the men (P less than 0.01). Blood pressure was lowered by prazosin in both supine and standing positions. Blood pressure control remained satisfactory in six of the eight women and the median prolongation of pregnancy was 22 days. Neonatal outcome was satisfactory and all babies are developing normally. We conclude that prazosin is more slowly, but apparently more completely, absorbed during pregnancy and that its half-life is slightly prolonged. Prazosin appears to be both effective and safe when used during the last trimester to control blood pressure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639840      PMCID: PMC1428072          DOI: 10.1111/j.1365-2125.1983.tb02213.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Some alterations in the pattern of drug metabolism aociated with pegnancy, oral contraceptives, and the newly-born.

Authors:  J S Crawford; S Rudofsky
Journal:  Br J Anaesth       Date:  1966-06       Impact factor: 9.166

Review 2.  Current concepts: beta-blockers in pregnancy.

Authors:  P C Rubin
Journal:  N Engl J Med       Date:  1981-11-26       Impact factor: 91.245

3.  Prazosin protein binding in health and disease.

Authors:  P Rubin; T Blaschke
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

4.  Drug disposition and pharmacokinetics in the maternal-placental-fetal unit.

Authors:  B Krauer; F Krauer; F E Hytten
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

5.  Prazosin first-pass metabolism and hepatic extraction in the dog.

Authors:  P Rubin; Y G Yee; M Anderson; T Blaschke
Journal:  J Cardiovasc Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.105

6.  Combined alpha- and beta-adrenoceptor antagonism with prazosin and oxprenolol in control of severe hypertension in pregnancy.

Authors:  W F Lubbe; J V Hodge
Journal:  N Z Med J       Date:  1981-09-09

7.  Prazosin determination by high-pressure liquid chromatography using fluorescence detection.

Authors:  Y G Yee; P C Rubin; P Meffin
Journal:  J Chromatogr       Date:  1979-04-21

8.  Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension.

Authors:  P C Rubin; L Butters; D M Clark; B Reynolds; D J Sumner; D Steedman; R A Low; J L Reid
Journal:  Lancet       Date:  1983-02-26       Impact factor: 79.321

9.  Fetal outcome in trial of antihypertensive treatment in pregnancy.

Authors:  C W Redman
Journal:  Lancet       Date:  1976-10-09       Impact factor: 79.321

10.  Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy.

Authors:  E D Gallery; D M Saunders; S N Hunyor; A Z Györy
Journal:  Br Med J       Date:  1979-06-16
View more
  10 in total

Review 1.  Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.

Authors:  P M Kyle; C W Redman
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

Review 2.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  The pharmacokinetics of oral indoramin during pregnancy.

Authors:  I Schabort; H J Odendaal; D M Pierce
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

4.  Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin.

Authors:  P Bourget; H Fernandez; D Edouard; A Lesne-Hulin; F Ribou; C Baton-Saint-Mleux; C Lelaidier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

Review 5.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 6.  Hypertension in pregnancy: a review of therapeutic options.

Authors:  D Kernaghan; A C Duncan; G A McKay
Journal:  Obstet Med       Date:  2012-02-17

Review 7.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

9.  Dwarfism and insulin resistance in male offspring caused by α1-adrenergic antagonism during pregnancy.

Authors:  Rebecca Oelkrug; Beate Herrmann; Cathleen Geissler; Lisbeth Harder; Christiane Koch; Hendrik Lehnert; Henrik Oster; Henriette Kirchner; Jens Mittag
Journal:  Mol Metab       Date:  2017-07-01       Impact factor: 7.422

10.  α 1-Adrenergic Receptor Blockade by Prazosin Synergistically Stabilizes Rat Peritoneal Mast Cells.

Authors:  Nozomu Abe; Hiroaki Toyama; Yutaka Ejima; Kazutomo Saito; Tsutomu Tamada; Masanori Yamauchi; Itsuro Kazama
Journal:  Biomed Res Int       Date:  2020-05-12       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.